Mr. Ibrahem/Lanreotide
Clinical data
Pronunciationlan ree' oh tide[1]
Trade namesSomatuline
Other namesLanreotide acetate
AHFS/Drugs.comMonograph
License data
Pregnancy
category
  • AU: C
Routes of
administration
Intramuscular, subcutaneous
Drug classSomatostatin analogue[2]
Legal status
Legal status
Pharmacokinetic data
BioavailabilityApproximately 80%
Protein binding78%
MetabolismIn GI tract
Elimination half-life2 hours (immediate release)
5 days (sustained release)
ExcretionMostly biliary
Identifiers
  • 3-(2-naphthyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-L-threoninamide (2->7)-disulfide
Chemical and physical data
FormulaC54H69N11O10S2
Molar mass1096.33 g/mol
1156.380 g/mol (acetate) g·mol−1
3D model (JSmol)
  • C[C@H]([C@@H](C(=O)N)NC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C(C)C)CCCCN)Cc2c[nH]c3c2cccc3)Cc4ccc(cc4)O)NC(=O)[C@@H](Cc5ccc6ccccc6c5)N)O
  • InChI=1S/C54H69N11O10S2/c1-29(2)45-54(75)63-44(53(74)65-46(30(3)66)47(57)68)28-77-76-27-43(62-48(69)38(56)23-32-15-18-33-10-4-5-11-34(33)22-32)52(73)60-41(24-31-16-19-36(67)20-17-31)50(71)61-42(25-35-26-58-39-13-7-6-12-37(35)39)51(72)59-40(49(70)64-45)14-8-9-21-55/h4-7,10-13,15-20,22,26,29-30,38,40-46,58,66-67H,8-9,14,21,23-25,27-28,55-56H2,1-3H3,(H2,57,68)(H,59,72)(H,60,73)(H,61,71)(H,62,69)(H,63,75)(H,64,70)(H,65,74)/t30-,38-,40+,41+,42-,43+,44+,45+,46+/m1/s1 ☒N
  • Key:PUDHBTGHUJUUFI-SCTWWAJVSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Lanreotide, sold under the brand name Somatuline, is a medication used to treat acromegaly, neuroendocrine tumors such as carcinoid, and thyroid tumors.[2] In acromegaly it is used when other treatments are not effective.[3] It is given by injection under the skin or into a muscle.[2]

Common side effects include diarrhea, abdominal pain, nausea, gallstones, joint pain, and pain at the site of injection.[3] Other side effects may include pancreatitis, high blood sugar, low blood sugar, and liver problems.[1] It is a somatostatin analogue and works by decreasing levels of growth hormone, insulin, and glucagon.[2][1]

Lanreotide was approved for medical use in the United States in 2007.[3] In the United Kingdom it costs the NHS about £550 at a dose of 60 mg per month as of 2021.[2] This amount in the United States costs about 6,100 USD.[4]

References edit

  1. ^ a b c "Lanreotide". LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases. 2012. Archived from the original on 20 November 2021. Retrieved 20 November 2021.
  2. ^ a b c d e f BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 993. ISBN 978-0857114105.
  3. ^ a b c d "Lanreotide Monograph for Professionals". Drugs.com. Archived from the original on 24 January 2021. Retrieved 20 November 2021.
  4. ^ "Somatuline Depot Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 17 April 2021. Retrieved 20 November 2021.